Comparison of Lentiviral and Sleeping Beauty Mediated αβ T Cell Receptor Gene Transfer

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Field, Anne Christine ^a   Vink, Conrad ^a   Gabriel, Richard ^b   Al Subki, Roua ^a   Schmidt, Manfred ^b   Goulden, Nicholas ^a   Stauss, Hans ^c   Thrasher, Adrian ^a   Morris, Emma ^c   Qasim, Waseem ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Institute of Immunity and Transplantation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; DNA; LENTIVIRUS VECTOR; PROTEIN SB100X; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSPOSASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CELLULAR DISTRIBUTION; CYTOLYSIS; DNA TRANSPOSITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMID; T LYMPHOCYTE RECEPTOR GENE; TRANSPOSON; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE, TUMOR; DNA TRANSPOSABLE ELEMENTS; GENE TRANSFER TECHNIQUES; GENES, T-CELL RECEPTOR; GENETIC THERAPY; GENETIC VECTORS; HUMANS; JURKAT CELLS; LENTIVIRUS; MICE; MICE, INBRED C57BL; PLASMIDS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

MURINAE;

EID: 84879545641     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068201     Document Type: Article

References (29)

1. Jena B, Dotti G, Cooper LJ, (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116: 1035-1044 blood-2010-01-043737 [pii];10.1182/blood-2010-01-043737 [doi].
2. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
3. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, Le Deist F, Wulffraat N, et al. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256.
4. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, et al. (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
5. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, et al. (2012) Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4: 132ra53 4/132/132ra53 [pii];10.1126/scitranslmed.3003761 [doi].
6. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med. 10.1056/NEJMoa1103849 [doi].
7. Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, et al. (2010) Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica 95: 126-134 haematol.2009.006486 [pii];10.3324/haematol.2009.006486 [doi].
8. Perro M, Tsang J, Xue SA, Escors D, Cesco-Gaspere M, et al. (2010) Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer. Gene Ther 17: 721-732 gt20104 [pii];10.1038/gt.2010.4 [doi].
9. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z, (1997) Molecular Reconstruction of Sleeping Beauty, a Tc1-like Transposon from Fish, and Its Transposition in Human Cells. Cell 91: 501-510.
10. Huang X, Guo H, Tammana S, Jung YC, Mellgren E, et al. (2010) Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. Mol Ther 18: 1803-1813 mt2010141 [pii];10.1038/mt.2010.141 [doi].
11. Huang X, Haley K, Wong M, Guo H, Lu C, et al. (2010) Unexpectedly high copy number of random integration but low frequency of persistent expression of the Sleeping Beauty transposase after trans delivery in primary human T cells. Hum Gene Ther 21: 1577-1590 10.1089/hum.2009.138 [doi].
12. Huang X, Wilber AC, Bao L, Tuong D, Tolar J, et al. (2006) Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood 107: 483-491.
13. Jin Z, Maiti S, Huls H, Singh H, Olivares S, et al. (2011) The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther. gt201140 [pii];10.1038/gt.2011.40 [doi].
14. Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, et al. (2013) Clinical application of sleeping beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp. 50070 [pii];10.3791/50070 [doi].
15. Mates L, Chuah MK, Belay E, Jerchow B, Manoj N, et al. (2009) Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 41: 753-761.
16. Mommaas B, van Halteren AG, Pool J, van d, V, Wieles B, et al. (2005) Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica 90: 1415-1421.
17. Demars R, Chang CC, Shaw S, Reitnauer PJ, Sondel PM (1984) Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum Immunol 11: 77-97. 0198-8859(84)90047-8 [pii].
18. Xue SA, Gao L, Hart D, Gillmore R, Qasim W, et al. (2005) Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 106: 3062-3067 2005-01-0146 [pii];10.1182/blood-2005-01-0146 [doi].
19. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, et al. (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13: 803-813.
20. Cui Z, Geurts AM, Liu G, Kaufman CD, Hackett PB, (2002) Structure-Function Analysis of the Inverted Terminal Repeats of the Sleeping Beauty Transposon. Journal of Molecular Biology 318: 1221-1235.
21. Vink CA, Gaspar HB, Gabriel R, Schmidt M, McIvor RS, et al. (2009) Sleeping beauty transposition from nonintegrating lentivirus. Mol Ther 17: 1197-1204.
22. Qasim W, Mackey T, Sinclair J, Chatziandreou I, Kinnon C, et al. (2007) Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction. Mol Ther 15: 355-360.
23. Arens A, Appelt JU, Bartholomae CC, Gabriel R, Paruzynski A, et al. (2012) Bioinformatic clonality analysis of next-generation sequencing-derived viral vector integration sites. Hum Gene Ther Methods 23: 111-118 10.1089/hgtb.2011.219 [pii];10.1089/hgtb.2011.219 [doi].
24. Pospori C, Xue SA, Holler A, Voisine C, Perro M, et al. (2011) Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. Blood 117: 6813-6824 blood-2010-08-304568 [pii];10.1182/blood-2010-08-304568 [doi].
25. Noser JA, Towers GJ, Sakuma R, Dumont JM, Collins MK, et al. (2006) Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J Virol 80: 7769-7774.
26. Cavalieri S, Cazzaniga S, Geuna M, Magnani Z, Bordignon C, et al. (2003) Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102: 497-505.
27. Vandendriessche T, Chuah MK, (2009) Moving gene therapy forward with mobile DNA. Hum Gene Ther 20: 1559-1561 10.1089/hum.2009.1109 [doi].
28. Maiti SN, Huls H, Singh H, Dawson M, Figliola M, et al. (2013) Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 36: 112-123 10.1097/CJI.0b013e3182811ce9 [doi]\.
29. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, et al. (2008) Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68: 2961-2971 68/8/2961 [pii];10.1158/0008-5472.CAN-07-5600 [doi].